Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
Oculis will host an in-person and virtual R&D Day at St. Regis New York on December 8, 2026, at 10:00 EST/16:00 CET. The event will spotlight its late-stage pipeline: Licaminlimab in TNFR1-mediated dry eye disease, with PREDICT-1 registrational topline results anticipated around year-end, and Privosegtor's PIONEER program in optic neuritis plus a planned first neurological indication in acute MS relapse, with IND clearance anticipated this quarter. Seven academic KOLs in ophthalmology and neurology will join management, and two recent neurology-focused hires will be introduced: CSO Prof.
Key figures
- Ind cleared expected
- Privosegtor IND clearance anticipated this quarter
- Topline results timing
- Licaminlimab PREDICT-1 topline results anticipated around year-end
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.